MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03288cam a2200397 a 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
17313952 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20160513093234.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
120522s2011 nyua b 001 0 eng c |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2012405289 |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
101555703 |
| Source |
DNLM |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781441973573 (alk. paper) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1441973575 (alk. paper) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781441973580 (eISBN) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1441973583 (eISBN) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)ocn648933300 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
SEKU |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC 271 .C5 |
| Item number |
P74 2011 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Principles of anticancer drug development / |
| Statement of responsibility, etc. |
edited by Manuel Hidalgo ... [et al.]. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
New York : |
| Name of publisher, distributor, etc. |
Springer, |
| Date of publication, distribution, etc. |
c2011. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xvii, 673 p. : |
| Other physical details |
ill. (some col.) |
| Dimensions |
25 cm. |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Cancer drug discovery and development |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 1# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Basic biostatistics for the clinical trialist / Elizabeth G. Hill and Elizabeth Garrett-Mayer -- Fundamental concepts in clinical pharmacology / Daniel L. Gustafson and Erica L. Bradshaw-Pierce -- Bioanalycial methods in clinical drug development / Walter J. Loos, Peter de Bruijn and Alex Sparreboom -- Preclinical models for anticancer drug development / Edward A. Sausville -- Phase I clinical trials with anticancer agents / Stephen Leong ... [et al.] -- Phase II trials with anticancer agents / Hui K. Gan, J. Jack Lee and Lillian L. Siu -- Phase III clinical trials with anticancer agents / Wendy R. Parulekar and Daniel J. Sargent -- Pharmacokinetic studies in early anticancer drug development / Alex Sparreboom and Sharyn D. Baker -- Pharmacodynamic studies in early phase drug development / D. Ross Camidge, Robert C. Doebele and Antonio Jimeno -- Prediction of antitumor response / Fred R. Hirsch and Yu Shyr -- Imaging studies in anticancer drug development / David A. Mankoff -- Role of the U.S. Food and drug administration in cancer drug development / Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur -- Early clinical trials with cytotoxic agents / M.J.A. de Jonge and Jaap Verweij -- Challenges and successes in developing effective anti-angiogenic agents / Laura Q.M. Chow and S. Gail Eckhardt -- Targeted therapeutics in cancer treatment / Colin D. Weekes and Manuel Hidalgo -- Cancer chemoprevention / Christopher H. Lieu, William N. William Jr. and Scott Lippman -- Combined modality therapy in cancer management / David Raben and Kyle Rusthoven -- Cancer vaccines / Daniel Laheru -- Optimising the development of antibodies as treatment for cancer / Craig P. Carden, Hendrik-Tobias Arkenau and Johann S. de Bono -- Oligonucleotide therapeutics / Cy A. Stein, Britta Hoehn and John Rossi -- Anticancer drug development in pediatric patients / Lia Gore and Margaret Macy -- Clinical trials in special populations / S. Percy Ivy ... [et al.] -- NCI-sponsored clinical trials / Andriana Papaconstantinou and Janet E. Dancey. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Antineoplastic agents. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug development. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Antineoplastic Agents |
| General subdivision |
therapeutic use. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug Discovery |
| General subdivision |
methods. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Clinical Trials as Topic. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug Approval. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Neoplasms |
| General subdivision |
drug therapy. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hidalgo, Manuel, |
| Titles and other words associated with a name |
MD. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Cancer drug discovery and development. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
General circulation |